Sentences with phrase «t cells in a tumor»

«There is a dramatic expansion of inhibitory T cells in the tumors after the infusion, much more significant than what you see without the CAR T cells,» O'Rourke said.

They applied epigenetic drugs and found that the numbers of T cells in the tumor increased.

In this study, we explored the antitumor potential of prostate stem cell antigen (PSCA)- redirected CAR T and mucin 1 (MUC1)- redirected CAR T cells in tumor models of NSCLC.

One found that people who had more T cells in their tumors before the treatment began tended to fare better.

Not exact matches

The latter «really just had quiescent T - cells in their tumors,» says Wargo.

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

These CAR - T cells were able to penetrate the blood - brain barrier, one of the major hurdles in treating brain tumors.

Furthermore, while the approach has shown tremendous promise in treating blood - based cancers like leukemia, solid tumors remain stubbornly difficult to treat with CAR T cells.

Even before treatment, cancer patients in the study had a small number of infection - and tumor - fighting T cells that target these unusual proteins, the researchers found.

«Combination therapy strengthens T cells in melanoma pre-clinical study: Findings have implications for treating tumors lacking tumor suppressor gene PTEN.»

A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the immune system's ability to kill melanoma tumors deficient in the tumor suppressor gene PTEN.

They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.

When the dendritic cells are activated, they train T cells — their allies in the adaptive arm of the immune system — to attack cancer cells anywhere in the body, whether at the site of the original tumor or distant metastases.

«To my great surprise, even injecting 10 million activated T cells specific to the P1A antigen did not affect tumor growth in this induced tumor model,» says Van den Eynde.

Since the cancer cells in both types of tumors were the same, the researchers compared the noncancerous cells present in the induced and transplanted tumors to explore what might be causing the T cell apoptosis.

Their paper, which appears in Nature Communications, describes how an immune cell recruited to the tumor induces the programmed suicide, or apoptosis, of the killer T cells harnessed by many immunotherapies.

In effect, PD - 1 may actually help to preserve a «reserve force» of T cells that can fight on later in the long - term cellular war between the immune system and foreign invaders or tumorIn effect, PD - 1 may actually help to preserve a «reserve force» of T cells that can fight on later in the long - term cellular war between the immune system and foreign invaders or tumorin the long - term cellular war between the immune system and foreign invaders or tumors.

In the mice that received GD2 CAR - T cells, the DIPG tumors were undetectable after 14 days, while mice receiving the control treatment had no tumor regression.

Next, the team tested the GD2 CAR - T cells in mice whose brainstem was implanted with human DIPG tumors, an experimental system that Monje's lab pioneered.

There is currently a PD - 1 antibody on the market that blocks T cell exhaustion in patients with solid tumors, like lung cancer and melanoma.

One advantage of this method is that it only activates a certain type of immune cell, the dendritic cell or T - cell, and only in one part of the body, near the draining lymph nodes or tumor, which helps cut down on the system - wide side effects often seen with chemotherapy.

«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.

Although changes in treatment methodology still have to be studied, Dr. Cripe believes it may be that the timing of various treatments is what matters, and that perhaps initially suppressing immunity could allow the virus to infect a large number of tumor cells before relieving the immunosuppression to allow the body's own T cells to fight off the tumor.

In principle, an attack by such T - cells on tumors should be particularly powerful as well as highly tumor - specific and thus sparing of healthy cells.

Half of the patients that could be evaluated showed big increases in the numbers of T - cells specifically reactive to tumor material, indicating a good response to vaccination.

In pancreatic cancer, their activity boosts tumor growth and spread, and may also help suppress T cells and other immune elements that would otherwise attack the tumor.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

Dana - Farber's Gordon Freeman, PhD, and his wife, Arlene Sharpe, MD, PhD, of Harvard Medical School, did some of the original research that resulted in the identification of PD - 1 on T cells, as well as the PD - L1 and - L2 protein «ligands» on tumor cells.

«This is a treatment that, rather than targeting cancer cells themselves, targets the immune response, reactivating the T cells in the neighborhood of the tumor cells,» Shipp remarked.

CTL119 manufacturing begins with a patient's own T cells, some of which are removed and then reprogrammed in Penn's Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to teach the T cells to target and kill tumor cells.

«Hodgkin lymphoma is unusual among cancers in that it consists of a small number of tumor cells in a sea of inflammatory cells and immune system cells, including T cells that don't work very effectively.»

In addition, when a subcutaneous tumor began to recur two months after CAR T - cell therapy and a surgical biopsy was performed, the CAR T - cells spontaneously re-expanded and the tumor again went into remission, and phenomenon that had not previously been reported.

Blood testing showed an expansion in the numbers of CD19 - targeted CAR T - cells that coincided with the tumor's regression.

Treatment with an investigational CAR T - cell therapy induced complete remission of a brain metastasis of the difficult - to - treat tumor diffuse large - B - cell lymphoma (DLBCL), which had become resistant to chemotherapy — the first report of a response to CAR T - cells in a central nervous system lymphoma.

The class of medications that he conceived, known as immune checkpoint inhibitors, works counterintuitively: By turning off one of the immune system's built - in safeguards, the inhibitors allow T cells — the system's foot soldiers — to attack tumors more effectively.

Subsequent surgery on vaccinated patients has shown that the T cells are finding and killing tumor cells in the brain, but not enough of them.

Researchers used IL - 15 to develop a whole tumor cell vaccine to target breast (TS / A) and prostate (TRAMP - C2) cancer cells in animal models; results showed that tumor cells stopped growing after the vaccine was introduced and that beneficial effects were enhanced further when IL - 15Rα was co-produced by the vaccine cells.

The good bacteria seem to help the drugs by priming T cells, which Wargo's group reported were more abundant in the gut and tumors of the mice who got fecal transplants from responder patients.

Increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune system's natural cancer - killing T - cells and caused primary tumors and metastatic tumors in the liver to shrink.

We have shown that T cells can locally produce commercial therapeutics (such as antibodies) in a solid tumor.

For most available T cell immunotherapies, T cells (which play a central role in defending the body against illness) are engineered to recognize and eliminate tumors, but their activity is not specifically controlled, leading to toxicity and unwanted side effects in patients as a result of inflammation or in some cases suboptimal response to treatment.

Mechanistic studies showed that IFN increases antitumor immune responses by enhancing antigen presentation to T cells by dendritic cells present in the tumor microenvironment.

«Recent successes in cancer immunotherapy — in the form of immune checkpoint inhibitors and adoptive T cell transfer — demonstrate how activated immune cells can eradicate tumors, but until now we didn't fully appreciate immunosurveillance or the role of adaptive immunity in tumor formation,» said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego School of Medicine.

Tumors exposed to LIGHT showed an influx of T - cells that resulted in rapid and sustained diminishment in size, even after expression of the cytokine stopped.

«The antibody - driven innate response creates an environment such that when the T cells come in, they can kill the tumor.

Tumors are home to diverse immune cell types, some of which remain much less explored than T cells and could also control cancer progression» says Mikael Pittet, PhD, director of the Cancer Immunology Program in the MGH Center for Systems Biology and senior author of the Science paper.

«This trial showed that there is a need to target additional antigens in glioblastoma, as well as overcome the immunosuppressive environment that the CAR T cells encountered in the tumor,» Maus said.

What's more, IL - 33 and the DNA vaccine augmented immunological responses in both CD4 helper T cells and CD8 killer T cells, with a large proportion of CD8 killer T cells demonstrating a further improvement in the ability of DNA vaccines to drive the immune system to kill tumor cells in animals.

Once activated, T cells can home in on a tumor and target it for destruction.

The paper identified two barriers: a wide variation in EGFRvIII expression in patients and a resistance in the tumor microenvironment, which researchers showed became even more immunosuppressive following CAR T cell infusion.